Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017 - Research and Markets

Research and Markets
Posted on: 20 Mar 17

Research and Markets has announced the addition of the "Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017" report to their offering.

The United States is the biggest generic drugs market in the world. In fact, nearly 80% of the prescriptions written in the US are for generic drugs.

Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017 - a comprehensive coverage of the generic drugs market in the United States. Beginning with a sectional description on generic drugs, the report covers topics such as the impact of the generics sector on major pharma companies, R&D strategies being implemented by major pharma companies in the generics sector, the long debate over generic drugs versus branded drugs, and much more - a cost analysis of branded drugs versus generic drugs being a highlight.

An overview of the global generics sector builds up the scene for the analysis of the US generics industry. The all-important Hatch-Waxman Framework, the DEFRA Regulation, and other recent regulatory measures are included in this analysis, along with the emerging issue of promoting generic drug competition in the US Market.

Being a major section of the report, Promoting Generic Drug Competition in the US Market covers topics such as issues with the FDA Approval Process, the role of the Orange Book, the positive and negative outcomes of the Hatch Waxman Act, the manipulation of this act, promoting methods for generic drug availability, amongst other points of discussion.

Strategies for survival employed by branded manufacturers, the role of generic drugs in lowering US drug re-importation, a case study on generic antidepressants, the approval of the generic version of GSK's drug Coreg, the introduction of Bill S.438, and the substantial move by Blue Cross in major changes to its drug plans, are discussed and analyzed in this report.

We also include a Porter's Five Forces analysis of the US Generic Drugs Industry.

Analysis of major industry players such as Teva Pharmaceutical Industry, Mylan N.V., Sandoz, Sanofi SA and others concludes this comprehensive research report.

Key Topics Covered:

A. Executive Summary

B. What are Generic Drugs?

C. Overview of the Global Generics Sector

D. Generics Industry in the United States

E. Generics Industry in the US: Porter's Five Forces Strategy Analysis

F. Pricing and Reimbursement of Generics in the US

G. Entry of Authorized Generics in the US Pharmaceutical Industry

H. Promoting Generic Drug Competition in the US Market

I. Strategies for Branded Manufacturers

J. Generic Drugs' Role in US Drug Re-importation

K. Case Study: Generic Antidepressants

L. Case Study: Major Change to Drug Plan by Blue Cross

M. Leading Industry Players

- Allergan Plc

- Mylan N.V.

- Par Pharmaceutical Companies, Inc.

- Sandoz International GmbH

- Sanofi SA

- Teva Pharmaceutical Industries

For more information about this report visit http://www.researchandmarkets.com/research/8c46pw/analyzing_the

View source version on businesswire.com: http://www.businesswire.com/news/home/20170320005987/en/

Business Wire
www.businesswire.com

Last updated on: 20/03/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.